Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas

Abstract Occurrence of resistance to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) approved in ovarian carcinoma, has already been shown in clinical settings. Identifying combination treatments to sensitize tumor cells and/or overcome resistance to olaparib is critical. Polo-like...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Michela Chiappa, Alessandra Decio, Luca Guarrera, Ilaria Mengoli, Anju Karki, Divora Yemane, Carmen Ghilardi, Eugenio Scanziani, Simone Canesi, Maria C. Barbera, Ilaria Craparotta, Marco Bolis, Robert Fruscio, Chiara Grasselli, Tommaso Ceruti, Massimo Zucchetti, Jesse C. Patterson, Robin A. Lu, Micheal B. Yaffe, Maya Ridinger, Giovanna Damia, Federica Guffanti
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Publishing Group 2024-07-01
سلاسل:	Cell Death and Disease
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41419-024-06894-1
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!